MX2024013068A - Métodos de administración de inhibidores de miosina - Google Patents
Métodos de administración de inhibidores de miosinaInfo
- Publication number
- MX2024013068A MX2024013068A MX2024013068A MX2024013068A MX2024013068A MX 2024013068 A MX2024013068 A MX 2024013068A MX 2024013068 A MX2024013068 A MX 2024013068A MX 2024013068 A MX2024013068 A MX 2024013068A MX 2024013068 A MX2024013068 A MX 2024013068A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- administering
- myosin
- inhibitors
- myosin inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B8/00—Diagnosis using ultrasonic, sonic or infrasonic waves
- A61B8/06—Measuring blood flow
- A61B8/065—Measuring blood flow to determine blood output from the heart
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H15/00—ICT specially adapted for medical reports, e.g. generation or transmission thereof
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H70/00—ICT specially adapted for the handling or processing of medical references
- G16H70/40—ICT specially adapted for the handling or processing of medical references relating to drugs, e.g. their side effects or intended usage
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medical Informatics (AREA)
- Primary Health Care (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Radiology & Medical Imaging (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263335028P | 2022-04-26 | 2022-04-26 | |
| US202263335209P | 2022-04-26 | 2022-04-26 | |
| US202263336254P | 2022-04-28 | 2022-04-28 | |
| PCT/US2023/019710 WO2023211872A1 (en) | 2022-04-26 | 2023-04-25 | Methods of administering myosin inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024013068A true MX2024013068A (es) | 2025-02-10 |
Family
ID=86558746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024013068A MX2024013068A (es) | 2022-04-26 | 2024-10-23 | Métodos de administración de inhibidores de miosina |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US20230338378A1 (https=) |
| EP (1) | EP4514355A1 (https=) |
| JP (1) | JP2025515491A (https=) |
| KR (1) | KR20250016125A (https=) |
| CN (2) | CN120549937A (https=) |
| AU (1) | AU2023260472A1 (https=) |
| CA (1) | CA3249509A1 (https=) |
| CL (1) | CL2024003237A1 (https=) |
| IL (1) | IL316204A (https=) |
| MX (1) | MX2024013068A (https=) |
| TW (1) | TW202400570A (https=) |
| WO (1) | WO2023211872A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020014428A2 (pt) | 2018-01-19 | 2020-12-01 | Cytokinetics, Inc. | composto, composição farmacêutica, e, métodos para o tratamento de uma doença cardíaca em um indivíduo, para o tratamento de uma doença ou condição que está associada com cavidade ventricular esquerda pequena e obliteração da cavidade, contração hiperdinâmica do ventrículo esquerdo, isquemia do miocárdio ou fibrose cardíaca, para o tratamento de uma doença ou condição selecionada dentre distrofias musculares e doenças de armazenamento do glicogênio e para inibição do sarcômero cardíaco |
| JP7610985B2 (ja) | 2018-06-26 | 2025-01-09 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| EP3814342B1 (en) | 2018-06-26 | 2022-07-27 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
| EP4370116B1 (en) | 2021-07-16 | 2025-01-15 | Cytokinetics, Inc. | Aficamten dosage regimens for treating obstructive hypertrophic cardiomyopathy |
| WO2024182469A1 (en) * | 2023-02-28 | 2024-09-06 | MyoKardia, Inc. | Myosin inhibitors for use in the treatment of hypertrophic cardiomyopathy |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9585885B2 (en) * | 2012-12-10 | 2017-03-07 | Kissei Pharmaceutical Co., Ltd. | Substituted pyrido[2,3-g]quinazolines as dopamine D2 receptor agonists |
| SMT202000071T1 (it) | 2013-06-21 | 2020-03-13 | Myokardia Inc | Composti di pirimidinadione contro le condizioni cardiache |
| BR112020014428A2 (pt) | 2018-01-19 | 2020-12-01 | Cytokinetics, Inc. | composto, composição farmacêutica, e, métodos para o tratamento de uma doença cardíaca em um indivíduo, para o tratamento de uma doença ou condição que está associada com cavidade ventricular esquerda pequena e obliteração da cavidade, contração hiperdinâmica do ventrículo esquerdo, isquemia do miocárdio ou fibrose cardíaca, para o tratamento de uma doença ou condição selecionada dentre distrofias musculares e doenças de armazenamento do glicogênio e para inibição do sarcômero cardíaco |
| JP7610985B2 (ja) | 2018-06-26 | 2025-01-09 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| EP3814342B1 (en) | 2018-06-26 | 2022-07-27 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
| JP7447089B2 (ja) | 2018-08-31 | 2024-03-11 | サイトキネティックス， インコーポレイテッド | 心筋サルコメア阻害剤 |
| CN114945372A (zh) * | 2019-11-10 | 2022-08-26 | 迈奥卡迪亚公司 | 用肌球蛋白调节剂的治疗方法 |
| CA3190060A1 (en) * | 2020-08-28 | 2022-03-03 | MyoKardia, Inc. | Methods of treatment with myosin modulator |
-
2023
- 2023-04-25 US US18/306,396 patent/US20230338378A1/en not_active Abandoned
- 2023-04-25 US US18/860,217 patent/US20250288586A1/en active Pending
- 2023-04-25 CA CA3249509A patent/CA3249509A1/en active Pending
- 2023-04-25 KR KR1020247038729A patent/KR20250016125A/ko active Pending
- 2023-04-25 WO PCT/US2023/019710 patent/WO2023211872A1/en not_active Ceased
- 2023-04-25 EP EP23726217.5A patent/EP4514355A1/en active Pending
- 2023-04-25 JP JP2024563614A patent/JP2025515491A/ja active Pending
- 2023-04-25 AU AU2023260472A patent/AU2023260472A1/en active Pending
- 2023-04-25 IL IL316204A patent/IL316204A/en unknown
- 2023-04-25 CN CN202510520246.XA patent/CN120549937A/zh active Pending
- 2023-04-25 CN CN202380047093.0A patent/CN119789856A/zh active Pending
- 2023-04-26 TW TW112115589A patent/TW202400570A/zh unknown
- 2023-12-20 US US18/390,537 patent/US20240115568A1/en active Pending
-
2024
- 2024-10-23 MX MX2024013068A patent/MX2024013068A/es unknown
- 2024-10-23 CL CL2024003237A patent/CL2024003237A1/es unknown
-
2025
- 2025-07-31 US US19/287,195 patent/US20250360132A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250360132A1 (en) | 2025-11-27 |
| AU2023260472A1 (en) | 2024-10-24 |
| WO2023211872A1 (en) | 2023-11-02 |
| US20230338378A1 (en) | 2023-10-26 |
| KR20250016125A (ko) | 2025-02-03 |
| IL316204A (en) | 2024-12-01 |
| CN120549937A (zh) | 2025-08-29 |
| US20250288586A1 (en) | 2025-09-18 |
| JP2025515491A (ja) | 2025-05-15 |
| CA3249509A1 (en) | 2023-11-02 |
| US20240115568A1 (en) | 2024-04-11 |
| TW202400570A (zh) | 2024-01-01 |
| CL2024003237A1 (es) | 2025-02-07 |
| CN119789856A (zh) | 2025-04-08 |
| EP4514355A1 (en) | 2025-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024013068A (es) | Métodos de administración de inhibidores de miosina | |
| MX2023005455A (es) | Metodos de tratamiento de la insuficiencia cardiaca mediante la administracion de omecamtiv mecarbil. | |
| ZA202104678B (en) | Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders | |
| NO20065676L (no) | Forebyggelse av arteriell restenose med aktive vitamin D forbindelser. | |
| MX2021002349A (es) | Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario. | |
| MX2023012875A (es) | Inhibidores 2-fluoro alquil-l,3,4-oxadiazol-5-il-tiazol de hdac6 para su uso en el tratamiento de enfermedades metabólicas y hfpef. | |
| MX2023001717A (es) | Composiciones y metodos de agentes de la ruta del estres replicativo para el tratamiento del cancer. | |
| MX2021013318A (es) | Terapias de combinacion que comprenden inhibidores de apremilast y tyk2. | |
| MX2025001990A (es) | Agente terapeutico y metodo terapeutico que son para pacientes con cancer que presentan deterioro funcional de la proteina del retinoblastoma (rb1) y que implican el uso concomitante de inhibidor del factor de transcripcion 1 de mielina (myt1) y agente quimioterapeutico | |
| MX2022014034A (es) | Métodos para tratar covid-19 con el uso de bardoxolona metilo o análogos de esta. | |
| WO2019010301A8 (en) | Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap) | |
| MX2021009384A (es) | Metodos para el tratamiento contra sintomas y trastornos asociados a enfermedades del almacenamiento lisosomico. | |
| MX2022008532A (es) | Inhibidores de hidrocarburo de arilo (ahr) y usos de estos. | |
| MX2022012001A (es) | Tratamiento preventivo de la migra?a. | |
| CA3156680A1 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF RETT SYNDROME | |
| EA202193276A1 (ru) | Способы лечения холангиокарциномы | |
| MX2023014778A (es) | Terapia de combinacion de radioinmunoconjugados e inhibidores de puntos de control. | |
| MX2025005021A (es) | Inhibidores de cromanona alostericos de fosfoinositido 3-quinasa (pi3k) para el tratamiento de enfermedades | |
| EP4208080A4 (en) | COMPOSITIONS AND METHODS FOR THE THERAPEUTIC TREATMENT OF PATIENTS WITH HEART FAILURE | |
| MX2023007420A (es) | Tratamiento de glomerulopatia c3 usando un inhibidor de c5a. | |
| AR129135A1 (es) | Métodos de administración de inhibidores de la miosina | |
| MX2020011912A (es) | Terapia de combinacion para el tratamiento del virus de la hepatitis c (vhc). | |
| WO2022171732A9 (en) | Composition and method for reducing oxalate levels in patients receiving maintenance dialysis | |
| MX2020007404A (es) | Metodos y terapia de combincion para tratar cancer. | |
| PH12021550134A1 (en) | Therapeutic or prophylactic agent for htlv-1-associated myelopathy (ham), and method for treating ham |